Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METRICS: Metabolic Medicines for Cancer
NCT02201381Phase 3Withdrawn
- Start
- May 2022
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of atorvastatin, metformin, doxycycline, mebendazole in cancer. Planned start May 2022; status: withdrawn.
02
Drugs
atorvastatinmetformindoxycyclinemebendazole
03
Conditions
cancer
Beyond the preview
Go deeper on NCT02201381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02201381.